We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+13.51%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.22B
AUM Growth
+$345M
Cap. Flow
-$140M
Cap. Flow %
-6.29%
Top 10 Hldgs %
38.04%
Holding
103
New
16
Increased
23
Reduced
25
Closed
12

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$82.9M
2
MCK icon
McKesson
MCK
+$64.6M
3
GKOS icon
Glaukos
GKOS
+$62M
4
VTRS icon
Viatris
VTRS
+$60.6M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$34.6M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$68.6M
2
GILD icon
Gilead Sciences
GILD
+$66.4M
3
NXTM
NxStage Medical Inc.
NXTM
+$60.1M
4
NVRO
NEVRO CORP.
NVRO
+$28M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$26.5M

Sector Composition

Rank Sector Weight
1 Healthcare 76.21%
2 Financials 0.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVXS
1
DELISTED
AveXis, Inc. Common Stock
AVXS
$150M 6.74%
1,547,386
-760,744
-33% -$68.6M
MCK icon
2
McKesson
MCK
$98.5B
$112M 5.04%
729,000
+413,583
+131% +$64.6M
VTRS icon
3
Viatris
VTRS
$20.1B
$98.9M 4.46%
3,153,611
+1,786,492
+131% +$60.6M
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$87.7M 3.95%
6,917,070
-2,081,343
-23% -$26.5M
GKOS icon
5
Glaukos
GKOS
$9.21B
$83.4M 3.76%
2,527,032
+1,632,481
+182% +$62M
MNK
6
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$69.5M 3.13%
1,860,137
+681,532
+58% +$27.1M
DXCM icon
7
DexCom
DXCM
$29.6B
$69.5M 3.13%
5,679,644
+4,688,280
+473% +$82.9M
MYOK
8
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$58.5M 2.63%
1,365,039
+1,085,287
+388% +$34.6M
NXTM
9
DELISTED
NxStage Medical Inc.
NXTM
$43.6M 1.96%
1,579,285
-2,254,045
-59% -$60.1M
BOLD
10
DELISTED
Audentes Therapeutics, Inc
BOLD
$42.7M 1.92%
1,525,410
-203,858
-12% -$4.43M
EDIT icon
11
Editas Medicine
EDIT
$457M
$41M 1.85%
1,709,400
– –
ACRS icon
12
Aclaris Therapeutics
ACRS
$793M
$40.7M 1.83%
1,577,927
+1,202,927
+321% +$32.2M
AVDL
13
DELISTED
Avadel Pharmaceuticals
AVDL
$38.4M 1.73%
3,655,494
– –
XENT
14
DELISTED
Intersect ENT, Inc
XENT
$37.7M 1.7%
1,210,000
+20,423
+2% +$604K
GWPH
15
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$36.8M 1.66%
362,724
+2,741
+0.8% +$294K
ASND icon
16
Ascendis Pharma A/S
ASND
$17.1B
$30.8M 1.39%
850,000
+430,547
+103% +$12.4M
AERI
17
DELISTED
Aerie Pharmaceuticals
AERI
$30.7M 1.39%
632,686
-328,461
-34% -$17.9M
ANAB icon
18
AnaptysBio
ANAB
$1.72B
$28.8M 1.3%
824,338
+271,479
+49% +$7.32M
NTRA icon
19
Natera
NTRA
$38.9B
$28.1M 1.27%
+2,181,542
New +$24.2M
DBVT
20
DBV Technologies
DBVT
$870M
$27.8M 1.25%
65,590
-930
-1% -$399K
PODD icon
21
Insulet
PODD
$11.4B
$27.4M 1.23%
+497,000
New +$27.1M
ARNA
22
DELISTED
Arena Pharmaceuticals Inc
ARNA
$27.3M 1.23%
1,072,329
+655,600
+157% +$15M
LCI
23
DELISTED
Lannett Company, Inc.
LCI
$26.8M 1.21%
363,315
-17,674
-5% -$1.3M
BCRX icon
24
BioCryst Pharmaceuticals
BCRX
$2.36B
$26.1M 1.17%
4,975,451
+1,476,249
+42% +$7.56M
XLRN
25
DELISTED
Acceleron Pharma
XLRN
$23M 1.03%
+615,000
New +$21.3M
1
2 3 4

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q3 2017 Portfolio in Review

As of Q3 2017, Deerfield Management held 103 positions worth $2.22B, up 18% from $1.87B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Deerfield Management withdrew a net $140M in Q3 2017, closing 12 positions and reducing 25 holdings. Its most notable exit was Gilead Sciences, an estimated $66.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, up from 72% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Insulet worth $27.4M.

  • Deerfield Management's largest Q3 2017 buy was Insulet: 497,000 shares worth $27.4M.
  • Deerfield Management added most to DexCom in Q3 2017, an estimated $82.9M increase.
  • Deerfield Management's biggest Q3 2017 reduction was AveXis, Inc. Common Stock, cutting an estimated $68.6M.
  • Deerfield Management fully exited Gilead Sciences in Q3 2017, selling an estimated $66.4M.
  • Deerfield Management's ten largest holdings make up 38% of its $2.22B portfolio in Q3 2017.
  • Deerfield Management opened 16 new positions and closed 12 in Q3 2017.
  • Deerfield Management's portfolio value rose 18% quarter-over-quarter to $2.22B.

Based on Deerfield Management's 13F filing for Q3 2017, filed 13 Nov 2017.